In 24 hours, $192 million in crypto liquidations hit short positions, impacting Bitcoin and Ethereum markets.In 24 hours, $192 million in crypto liquidations hit short positions, impacting Bitcoin and Ethereum markets.

Crypto Market Sees $192 Million Liquidations in a Day

Crypto Market Sees $192 Million Liquidations in a Day
Key Takeaways:
  • Major liquidations primarily affected short positions.
  • Bitcoin surge pushed prices beyond $65,700.
  • Liquidations could boost bullish market momentum.

In the last 24 hours, $192 million in crypto positions were liquidated, primarily from short positions. The surge in Bitcoin’s price beyond $65,700 contributed significantly to these liquidations by forcing many bearish leveraged positions to close.

In the last 24 hours, $192 million in crypto positions were liquidated, primarily impacting short positions. The market activity was driven by a Bitcoin price rally that surged past $65,700.

Bitcoin’s sharp price increase has stirred significant market reactions, leading to widespread liquidations and consolidating a trend towards bullish momentum.

In the recent 24-hour period, crypto trading platforms witnessed extensive liquidations, dominated by short positions totaling $114 million. This trend emerged in parallel with an upward price rally in Bitcoin.

Major industry players like Binance and OKX historically play crucial roles during such market activities. The absence of commentary from prominent figures suggests a focus on internal assessments despite the high-stakes market shifts.

The immediate aftermath includes enhanced volatility, particularly affecting Bitcoin and Ethereum markets. Liquidations on such a scale have significantly altered trading dynamics.

Previous events show that during high-volatility phases like this, markets often recalibrate, leading to combined effects on futures, options, and derivatives trading.

As crypto markets continue evolving, understanding these patterns remains vital for stakeholders globally. Historical data suggests similar events could lead to more robust protective measures from exchanges focusing on user fund security.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26